NLRP3 and atherosclerosis: Evidence for the driving role of NLRP3 and NLRP3-mediated IL-1β production in the progression of cardiovascular disease was demonstrated in the CANTOS study, a randomized placebo-controlled and world-wide study in 10,067 patients with atherosclerosis.